Stockreport

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview ...

Intensity Therapeutics, Inc.  (INTS) 
PDF SHELTON, Conn. and BERN, Switzerland Dec. 12, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc . ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical bi [Read more]